louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02124408: Mobile Phone Personalized Intervention for Diabetes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Ningbo Beilun District Traditional Chinese Medicine Hospital
Sponsor class: OTHER
First posted: 2014-04-28
Enrollment: 500
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: With the development of economy and change of lifestyles, it is characterized that there is a dramatic increase of diabetes in China. Changes in lifestyle/self-care behaviors by diabetes patients are required to improve blood glucose and subsequent outcomes. Mobile phone intervention was a kind of high cost efficiency and high quality health care. Our study evaluated a diabetes coaching system, using mobile phones and patient/provider portals for patient-specific treatment and communication.


Eligibility criteria: Inclusion Criteria:

1. Physician diagnosis of type 2 diabetes
2. Age 20 years and more
3. The local resident

Exclusion Criteria:

1. Not currently managed by study physicians
2. Pregnant
3. Active substance, alcohol, or drug abuser
4. Psychotic or schizophrenic under activecare
5. Severe hearing or visual impairment
6. No telephone or mobile phone

Primary outcomes:
measure: change in glycated hemoglobin levels
timeFrame: baseline and 6 months
Secondary outcomes:
measure: changes in patient-reported diabetes symptoms
timeFrame: baseline and 6 months
measure: control of diabetic complications
timeFrame: baseline and 6 months
Other outcomes:
Locations:
city: Ningbo
country: China
facility: Ningbo Beilun District Traditional Chinese Medicine Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT01934608: The Effect of Synching Prescription Refills on Adherence
Official title: A Randomized Controlled Trial to Test a Synchronized Prescription Refill Program to Improve Medication Adherence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Hypercholesterolemia
Diabetes
Medication Adherence
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2013-09-04
Enrollment: 691
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To determine the effect of synchronizing a patient's prescription refill schedule on medication adherence. The targeted population is Humana members who are currently taking 2 or more Stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of RightSource. Participants will be randomized to one of two groups. Group one will be usual care and group two will be the Rx synchronization group.


Eligibility criteria: Inclusion Criteria:

* Humana members who are currently taking 2 or more Stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of RightSource.

Exclusion Criteria:

* under 18 years of age

Primary outcomes:
measure: Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure
timeFrame: 6 months and 12 months
Secondary outcomes:
measure: Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.
timeFrame: 6 and 12 months
Other outcomes:
Locations:
city: Louisville
country: United States
facility: Humana, Inc
state: Kentucky
Study officials:
affiliation: University of Pennsylvania
name: Jalpa Doshi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05587608: US-guided Thoracic Spinal Epidural Anesthesia VS GA for Abdominal and Breast Surgeries
Official title: US-guided Combined Segmental Thoracic Spinal Epidural Anesthesia in Comparison With General Anesthesia for Upper Abdominal and Breast Surgeries - A Randomized Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Lead sponsor: South Egypt Cancer Institute
Sponsor class: OTHER
Collaborators: name: Assiut University
First posted: 2022-10-20
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Ultrasound-guided combined thoracic segmental spinal epidural anesthesia in comparison with general anesthesia in upper abdominal and breast surgery.

Detailed description: The first group (S) will be given ultrasound-guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space, patients will be in sitting position, a combined spinal epidural tray will be used. In this group, SonoSite C60x/5-2 MHz M-Turbo Convex Probe ultrasound Transducer to identify the T10 interlaminar space and after complete sterilization, the investigator will introduce the epidural needle in a Paramedian in plan approach till the epidural space. The spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle. The epidural catheter is then threaded through the Touhy needle after withdrawal of the spinal needle to keep only 4cm up in the epidural space.

Eligibility criteria: Inclusion Criteria:

* All upper abdominal and laparoscopic surgeries
* ASA I-III CLASS
* Age between 18 and 60

Exclusion Criteria:

Contraindication of regional ASA More than III Age less than18 or more than 60 Psychological troubles

Primary outcomes:
measure: MAP
timeFrame: Change from Baseline Systolic Blood Pressure at one day post operative
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt
Study officials:
References:
Clinical trial NCT03034408: Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects
Official title: Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alcohol Use Disorder
Keywords: Impulsivity
Nalmefene
Baclofen
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Impulsivity is a central feature of addiction. Nalmefen is an authorized treatment for alcohol addiction. Baclofen has empathically been advocated to have some efficacy in this indication. The aim of the present study is to test the effect of Nalmefene and Baclofen on impulsivity.

Primary study objective: To examine the effect of Nalmefene and Baclofen on impulsivity (as measured by the Stop Signal Task) in subjects with alcohol use disorder and healthy control subjects.

Main secondary study objectives: To examine the effect of Nalmefene and Baclofen on risk taking (as measured by the Balloon Analogue Risk Task) and on the preference for small immediate rewards over large delayed rewards (as measured by the Delay Discounting Task). To compare subjects with alcohol use disorder and healthy control subjects on these tasks.

Primary study outcome: Stop-signal reaction time in the Stop-Signal Task Main secondary study outcomes: Equivalence point in the Delay-Discounting Task and Average number of pumps delivered in the Balloon Analogue Risk Task

Study Design: Randomized, placebo control, cross-over, single-dose


Eligibility criteria: Inclusion Criteria:

* 30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20),
* 30 sex and age-matched healthy controls,
* over 18, informed consent.

Exclusion Criteria:

* opiate-treatment,
* contra-indications for Nalmefene and/or Baclofen,
* unstable psychiatric disorder,
* pregnancy,
* acute withdrawal syndrome.

Primary outcomes:
measure: Change in "Stop-signal reaction time" in the Stop-Signal Task
timeFrame: 0 and 2 hours post-dose
Secondary outcomes:
measure: Change in "Equivalence point" in the Delay-Discounting Task
timeFrame: 0 and 2 hours post-dose
measure: Change in "Average number of pumps" delivered in the Balloon Analogue Risk Task
timeFrame: 0 and 2 hours post-dose
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Service d'Addictologie, Hôpitaux Universitaires de Genève
Study officials:
affiliation: University Hospital, Geneva
name: Daniele F Zullino, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02042508: Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.
Official title: Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Paraplegia
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2014-01-23
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: This single-centre study was carried out in collaboration with the Cardiovascular Research Laboratory of Harvard University (Boston, USA). This preliminary study does not include a control group.

The aim of this study was to investigate the effect of a hybrid reconditioning programme (electrostimulation of the lower limb muscles associated with voluntary strengthening of the upper limbs) on a specially developed rowing machine in patients presenting stabilized paraplegia of a traumatic origin. This study will bear on the increase in maximal aerobic capacity (VO2max) between the start and end of the 9-month reconditioning programme.


Eligibility criteria: Inclusion Criteria:

* Male or female patients with paraplegia, ageb between 18 and 45 years
* Body mass index (BMI) between 18.5 and 29.9
* 2 to 15 years after the accident, ASIA A or B, lesion situated between T3 and T12
* Medically stable
* Able to follow instructions
* Persons who have provided written informed consent

Exclusion Criteria:

* Persons without national health insurance cover
* Arterial blood pressure \> 140/90 mmHg, arrythmia, heart disease, diabetes, impaired kidney function, cancer
* smoking-induced intoxication,
* Medical treatment for cardiovascular disease or antidepressants
* Orthostatic hypotension with a symptomatic fall in arterial pressure \> 30 mmHg in the vertical position
* Grade 2 or more pressure sores
* Other associated neurological diseases (e.g. cerebrovascular accident, peripheral neuropathy, myopathy)
* Any disease affecting the shoulder that may compromise the ability to use the rowing machine.
* Coagulation disorders;
* Presence of an implanted electronic device
* Epilepsy

Primary outcomes:
measure: Maximal oxygen consumption (VO2max) measured during an incremental maximum effort test
timeFrame: Change from baseline in VO2max at 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU de Dijon
Study officials:
References:
Clinical trial NCT03070808: The Influence of Significant Weight Lost on the Quality of Voice
Official title: The Influence of Significant Weight Lost on the Quality of Voice
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity, Morbid
Voice Alteration
Keywords: obesity
voice
Lead sponsor: Kaplan Medical Center
Sponsor class: OTHER
First posted: 2017-03-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults, 18 years and over, entended for Bariatric Surgery at Kaplan Medicle Center.

Brief summary: The rate of obesity and bariatric surgery is rising steadily. Though Bariatric Surgery Influences on aspects such as endocrin analysis, finance, etc are well tested, quantitative and quality voice impacts have not been evaluated. The aim of the study is to recruit 50 patients who underwent bariatric surgery and compare voice quality in each of these patients before and after surgery.


Eligibility criteria: Inclusion Criteria:

* Morbid obese
* Candidates for bariatric Surgery

Exclusion Criteria:

* History of benign \\ malignant disease of the larynx.
* History of head and neck tumors
* History of radiation therapy of the neck
* BMI under 30 pre-surgery

Primary outcomes:
measure: Stroboscopic evaluation of the larynx
timeFrame: 2/16-2/20
Secondary outcomes:
measure: Dysphagia handicap Index
timeFrame: 2/16-2/20
measure: EAT 10
timeFrame: 2/16-2/20
measure: Voice Handicap Index
timeFrame: 2/16-2/20
measure: Average Fundamental frequency
timeFrame: 2/16-2/20
measure: Mean Fundamental frequency
timeFrame: 2/16-2/20
measure: Highest Fundamental frequency
timeFrame: 2/16-2/20
measure: Lowest Fundamental frequency
timeFrame: 2/16-2/20
measure: Standard deviation of Fundamental frequency
timeFrame: 2/16-2/20
measure: Noise to harmonic ratio
timeFrame: 2/16-2/20
measure: Voice turbulence Index
timeFrame: 2/16-2/20
measure: Absolute gitter
timeFrame: 2/16-2/20
measure: Jitter percent
timeFrame: 2/16-2/20
measure: Shimmer percent
timeFrame: 2/16-2/20
measure: Shimmer in dB
timeFrame: 2/16-2/20
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00407108: Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Diabetic Retinopathy
Keywords: vitreoretinal surgery
Lead sponsor: Asociación para Evitar la Ceguera en México
Sponsor class: OTHER
First posted: 2006-12-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate the feasibility and advantages of using perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting vitrectomy using a dual, dynamic drive (3D)technology. In complicated surgeries in advanced diabetic retinopathy and retinal detachment


Eligibility criteria: Inclusion Criteria:

* Advanced diabetic retinopathy with retinal detachment

Exclusion Criteria:

* Retinal detachments of more than 6 months

Primary outcomes:
measure: Surgical time
measure: Facility of surgical maneuvers
Secondary outcomes:
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Asociación para Evitar la Ceguera en Mexico, Hospital "Luis Sanchez Bulnes"
state: Mexico DF
Study officials:
affiliation: Asociación para Evitar la Ceguera en México
name: Hugo Quiroz-Mercado, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00338208: Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot
Official title: Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: low vision
glaucoma
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2006-06-20
Enrollment: 2
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We wish to evaluate a potential training program for patients with glaucoma, to become more efficient users of prescribed low vision devices for distance and near vision tasks. We hypothesize that the devices will improve efficiency. Prescribed devices will include a stand magnifier, a handheld magnifier, spectacle magnifiers for near vision, and a handheld monocular (telescope) and a bioptic telescope (spectacle-mounted telescope) for distance vision. The success of being able to use optical devices is dependent upon training. Optical devices are currently accepted and used for patients with visual conditions that decrease their central vision. The bioptic telescope is a pair of glasses with a small telescope mounted within the carrier lens. The glasses look and feel like a normal pair of glasses, but have a black device (telescope) protruding from the top of one lens for better identifying distance objects. The spectacle magnifier is mounted in a pair of glasses also for near vision

Detailed description: You will be asked a series of oral questions regarding your health status and vision level of functioning (Expectations of Visual Functioning Form, NEI-VFQ, Linear Rating Scale, and Geriatric Depression Scale) in the Vanderbilt Eye Clinic. You will undergo a mobility pre-test to assess your ability to find objects in the distance as well as read . You will undergo a low vision examination in the eye clinic. You will receive the optical devices and then receive brief instructions on the use of the devices . You will then undergo a pre-training evaluation. You will receive approximately 6 training sessions with your prescribed devices for up to 1 hour each time. You will return to the Vanderbilt Eye Clinic for the post-training distance and near vision assessments with the devices . You will be asked the series of oral questions again regarding your health status and vision level of functioning .

Eligibility criteria: Inclusion Criteria:

* Glaucoma patients with vision less than 20/40

Exclusion criteria:

- Subjects must not have any significant physical mobility limitations and be willing to participate in the testing and training sessions.

Primary outcomes:
measure: mobility
timeFrame: At time of enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Karen Joos, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04786808: Risk Factors for COVID-19 Mortality
Official title: Risk Factors for COVID-19 Mortality: a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: COVID-19 Virus Infection
Population at Risk
Acute Respiratory Distress Syndrome
Lead sponsor: Azienda Unita Sanitaria Locale di Piacenza
Sponsor class: OTHER
First posted: 2021-03-08
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients admitted to the ward from the Emergency Department are proposed to participate to the study.

Patients admitted to the Emergency Medicine Ward have a COVID-19 pneumonia with respiratory failure at any stage of severity, with a PaO2/FiO2 ratio approximately between 100 and 300. Prevalence of severe cases changes according to the number of cases diagnosed in the community and consequently to the global number of admissions to the hospital. The study is intended to be conducted over a period of 1 year.

Brief summary: COVID-19 pandemic has deeply burdened hospitals all over the world. A two-stage disease has been hypothesized due to quick worsening of clinical status after 7-10 days from the beginning of first symptoms, generally flu-like symptoms. Predicting clinical worsening could help to address major efforts towards higher risk patients.

During the last year most observational studies, generally retrospective, has been conducted, identifying some risk factors such as age, obesity, male gender, cardiovascular disease, COPD, diabetes etc.

The study goal is to collect systematically a variegate amount of clinical, biometric, laboratory and radiological data from patients admitted to the Emergency Medicine Ward of Piacenza Hospital (Italy), in order to prospectively analyze what characteristics are associated to higher risk of mortality.


Eligibility criteria: Inclusion Criteria:

* Admission to the Emergency Medicine Ward from the Emergency Department of Piacenza Hospital (Italy)
* Confirmed COVID-19 diagnosis through molecular test obtained from nasal-pharyngeal swabs in the Emergency Department
* Age above 18

Exclusion Criteria:

* inability to obtain an informed consent due to neurological conditions.
* patient's refusal to sign the informed consent
* inability of researchers to recruit the patient in the first 24 hours from the admission.

Primary outcomes:
measure: Mortality rate
timeFrame: 28 days after admission
Secondary outcomes:
measure: Need of invasive ventilation
timeFrame: 15 days after admission
Other outcomes:
Locations:
city: Piacenza
country: Italy
facility: Azienda USL di Piacenza
state: Emilia-Romagna
Study officials:
References:
Clinical trial NCT06045208: Foot and Lower Extremity Exercises in Adolescents With Pes Planovalgus
Official title: Comparison of the Effects of Foot and Lower Extremity Strengthening Exercises in Adolescents With Pes Planovalgus
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Flat Foot
Keywords: exercise
foot posture
foot kinematic
Lead sponsor: Istanbul Kültür University
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 45
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The study aims to determine and compare the effects of 8-week intrinsic foot muscle-strengthening exercises and lower extremity strengthening exercises in adolescents with pes planovalgus.


Eligibility criteria: Inclusion Criteria:

* Age between the 12-18 years,
* Foot posture index-6 score \> 6,
* Navicular drop test value \> 1 cm,
* Body mass index between 18.5 - 25 kg/m2,
* Children with flexible pes planovalgus

Exclusion Criteria:

* Presence of any pathology that prevents participation in exercises
* Diagnosis of any neurological, psychological, or metabolic disease
* History of orthopedic surgery
* Use of insoles in the last 1 year
* Leg length discrepancy and scoliosis

Primary outcomes:
measure: Foot posture assesment
timeFrame: Pre-intervention assesment and after 8-week
measure: Foot muscle strentgh assesment
timeFrame: Pre-intervention assesment and after 8-week
measure: Performance and dynamic balance assesment
timeFrame: Pre-intervention assesment and after 8-week
measure: 3D gait analysis
timeFrame: Pre-intervention assesment and after 8-week
Secondary outcomes:
measure: Functional assesment
timeFrame: Pre-intervention assesment and after 8-week
measure: Quality of life assesment
timeFrame: Pre-intervention assesment and after 8-week
Other outcomes:
Locations:
Study officials:
affiliation: Istanbul University - Cerrahpasa
name: Halenur Evrendilek, MSc, PhD (c)
role: PRINCIPAL_INVESTIGATOR
affiliation: Istanbul University - Cerrahpasa
name: Derya Çelik, Prof. Dr.
role: STUDY_DIRECTOR
References: